Illumina Inc. (ILMN)

$140.14

+3.15

(+2.3%)▲

Market is closed - opens 8 PM, 25 Nov 2024

Performance

  • $136.98
    $141.37
    $140.14
    downward going graph

    2.25%

    Downside

    Day's Volatility :3.1%

    Upside

    0.87%

    downward going graph
  • $93.51
    $156.66
    $140.14
    downward going graph

    33.27%

    Downside

    52 Weeks Volatility :40.31%

    Upside

    10.55%

    downward going graph

Returns

PeriodIllumina Inc.Sector (Health Care)Index (NASDAQ Composite)
3 Months
6.66%
-7.3%
6.3%
6 Months
32.39%
-0.5%
13.5%
1 Year
42.51%
10.5%
33.2%
3 Years
-61.68%
8.8%
20.5%

Highlights

Market Capitalization
21.7B
Book Value
$13.45
Earnings Per Share (EPS)
-9.97
PEG Ratio
0.62
Wall Street Target Price
164.597
Profit Margin
-36.11%
Operating Margin TTM
23.98%
Return On Assets TTM
2.62%
Return On Equity TTM
-39.51%
Revenue TTM
4.4B
Revenue Per Share TTM
27.65
Quarterly Revenue Growth YOY
-3.5000000000000004%
Gross Profit TTM
3.1B
EBITDA
730.0M
Diluted Eps TTM
-9.97
Quarterly Earnings Growth YOY
-0.96
EPS Estimate Current Year
4.12
EPS Estimate Next Year
4.45
EPS Estimate Current Quarter
0.88
EPS Estimate Next Quarter
0.94

Analyst Recommendation

Buy
    46%Buy
    43%Hold
    10%Sell
Based on 30 Wall street analysts offering stock ratings for Illumina Inc.(by analysts ranked 0 to 5 stars)
Based on 30 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
14
14
14
Hold
13
13
13
Sell
3
3
3

Analyst Forecast

What analysts predicted

Upside of 17.45%

Current $140.14
Target $164.60

Company Financials

FY18Y/Y Change
Revenue
3.3B
↑ 21.11%
Net Income
826.0M
↑ 13.77%
Net Profit Margin
24.78%
↓ 1.6%
FY19Y/Y Change
Revenue
3.5B
↑ 6.3%
Net Income
1.0B
↑ 21.31%
Net Profit Margin
28.28%
↑ 3.5%
FY20Y/Y Change
Revenue
3.2B
↓ 8.58%
Net Income
656.0M
↓ 34.53%
Net Profit Margin
20.25%
↓ 8.03%
FY21Y/Y Change
Revenue
4.5B
↑ 39.73%
Net Income
762.0M
↑ 16.16%
Net Profit Margin
16.84%
↓ 3.41%
FY22Y/Y Change
Revenue
4.6B
↑ 1.28%
Net Income
-4.4B
↓ 677.95%
Net Profit Margin
-96.07%
↓ 112.91%
FY23Y/Y Change
Revenue
4.5B
↓ 1.75%
Net Income
-1.2B
↓ 73.64%
Net Profit Margin
-25.78%
↑ 70.29%
Q2 FY23Q/Q Change
Revenue
1.2B
↑ 8.19%
Net Income
-234.0M
↓ 7900.0%
Net Profit Margin
-19.9%
↓ 20.18%
Q3 FY23Q/Q Change
Revenue
1.1B
↓ 4.85%
Net Income
-754.0M
↑ 222.22%
Net Profit Margin
-67.38%
↓ 47.48%
Q4 FY23Q/Q Change
Revenue
1.1B
↑ 0.27%
Net Income
-176.0M
↓ 76.66%
Net Profit Margin
-15.69%
↑ 51.69%
Q1 FY24Q/Q Change
Revenue
1.1B
↓ 4.1%
Net Income
-126.0M
↓ 28.41%
Net Profit Margin
-11.71%
↑ 3.98%
Q2 FY24Q/Q Change
Revenue
1.1B
↑ 3.35%
Net Income
-2.0B
↑ 1477.78%
Net Profit Margin
-178.78%
↓ 167.07%
Q3 FY24Q/Q Change
Revenue
1.1B
↓ 2.88%
Net Income
705.0M
↓ 135.46%
Net Profit Margin
65.28%
↑ 244.06%
FY18Y/Y Change
Total Assets
7.0B
↑ 32.38%
Total Liabilities
3.1B
↑ 29.05%
FY19Y/Y Change
Total Assets
7.3B
↑ 5.13%
Total Liabilities
2.7B
↓ 13.2%
FY20Y/Y Change
Total Assets
7.6B
↑ 3.68%
Total Liabilities
2.9B
↑ 6.96%
FY21Y/Y Change
Total Assets
15.2B
↑ 100.62%
Total Liabilities
4.5B
↑ 54.86%
FY22Y/Y Change
Total Assets
12.3B
↓ 19.48%
Total Liabilities
5.7B
↑ 26.27%
FY23Y/Y Change
Total Assets
10.1B
↓ 17.47%
Total Liabilities
4.4B
↓ 22.77%
Q2 FY23Q/Q Change
Total Assets
11.8B
↓ 0.31%
Total Liabilities
5.2B
↑ 1.97%
Q3 FY23Q/Q Change
Total Assets
10.1B
↓ 14.03%
Total Liabilities
4.2B
↓ 19.06%
Q4 FY23Q/Q Change
Total Assets
10.1B
↓ 0.11%
Total Liabilities
4.4B
↑ 3.36%
Q1 FY24Q/Q Change
Total Assets
10.0B
↓ 0.7%
Total Liabilities
4.3B
↓ 1.37%
Q2 FY24Q/Q Change
Total Assets
6.1B
↓ 39.43%
Total Liabilities
4.6B
↑ 7.87%
Q3 FY24Q/Q Change
Total Assets
6.0B
↓ 1.1%
Total Liabilities
3.9B
↓ 16.28%
FY18Y/Y Change
Operating Cash Flow
1.1B
↑ 30.51%
Investing Cash Flow
-1.8B
↑ 747.2%
Financing Cash Flow
594.0M
↓ 437.5%
FY19Y/Y Change
Operating Cash Flow
1.1B
↓ 7.97%
Investing Cash Flow
745.0M
↓ 141.09%
Financing Cash Flow
-897.0M
↓ 251.01%
FY20Y/Y Change
Operating Cash Flow
1.1B
↑ 2.76%
Investing Cash Flow
-554.0M
↓ 174.36%
Financing Cash Flow
-766.0M
↓ 14.6%
FY21Y/Y Change
Operating Cash Flow
545.0M
↓ 49.54%
Investing Cash Flow
-1.1B
↑ 92.96%
Financing Cash Flow
-51.0M
↓ 93.34%
FY22Y/Y Change
Operating Cash Flow
392.0M
↓ 28.07%
Investing Cash Flow
-591.0M
↓ 44.71%
Financing Cash Flow
1000.0M
↓ 2060.78%
Q2 FY23Q/Q Change
Operating Cash Flow
105.0M
↑ 950.0%
Investing Cash Flow
-37.0M
↓ 33.93%
Financing Cash Flow
-3.0M
↓ 99.37%
Q3 FY23Q/Q Change
Operating Cash Flow
139.0M
↑ 32.38%
Investing Cash Flow
-146.0M
↑ 294.59%
Financing Cash Flow
-707.0M
↑ 23466.67%

Technicals Summary

Sell

Neutral

Buy

Illumina Inc. is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Illumina Inc.
Illumina Inc.
-1.96%
32.39%
42.51%
-61.68%
-55.82%
Idexx Laboratories, Inc.
Idexx Laboratories, Inc.
-8.88%
-19.16%
-12.74%
-32.7%
65.66%
Agilent Technologies Inc.
Agilent Technologies Inc.
0.61%
-11.1%
5.7%
-13.53%
66.76%
Thermo Fisher Scientific, Inc.
Thermo Fisher Scientific, Inc.
-10.97%
-12.27%
4.58%
-18.89%
65.25%
Danaher Corp.
Danaher Corp.
-7.87%
-9.78%
6.52%
-24.78%
62.72%
Iqvia Holdings Inc.
Iqvia Holdings Inc.
-11.6%
-11.13%
-4.81%
-23.92%
37.77%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Illumina Inc.
Illumina Inc.
91.22
NA
0.62
4.12
-0.4
0.03
NA
13.45
Idexx Laboratories, Inc.
Idexx Laboratories, Inc.
40.32
40.32
4.41
10.73
0.59
0.23
NA
19.72
Agilent Technologies Inc.
Agilent Technologies Inc.
27.46
27.46
2.77
5.24
0.25
0.08
0.01
20.53
Thermo Fisher Scientific, Inc.
Thermo Fisher Scientific, Inc.
32.36
32.36
1.95
21.69
0.13
0.05
0.0
128.08
Danaher Corp.
Danaher Corp.
44.43
44.43
2.74
7.5
0.08
0.04
0.0
71.03
Iqvia Holdings Inc.
Iqvia Holdings Inc.
26.52
26.52
1.03
11.14
0.22
0.05
NA
38.37
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Illumina Inc.
Illumina Inc.
Buy
$21.7B
-55.82%
91.22
-36.11%
Idexx Laboratories, Inc.
Idexx Laboratories, Inc.
Buy
$34.3B
65.66%
40.32
22.53%
Agilent Technologies Inc.
Agilent Technologies Inc.
Buy
$37.9B
66.76%
27.46
21.75%
Thermo Fisher Scientific, Inc.
Thermo Fisher Scientific, Inc.
Buy
$197.4B
65.25%
32.36
14.48%
Danaher Corp.
Danaher Corp.
Buy
$169.8B
62.72%
44.43
16.39%
Iqvia Holdings Inc.
Iqvia Holdings Inc.
Buy
$36.6B
37.77%
26.52
9.17%

Insights on Illumina Inc.

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 1.11B → 1.08B (in $), with an average decrease of 2.9% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, -1.98B → 705.0M (in $), with an average increase of 382.0% per quarter

  • Vs A

    In the last 3 years, Illumina Inc. has experienced a drawdown of -61.7%, however Agilent Technologies Inc. resisted the overall trend and outperformed by 48.2%

Institutional Holdings

  • BlackRock Inc

    11.44%

  • Vanguard Group Inc

    10.07%

  • State Street Corp

    3.54%

  • Loomis, Sayles & Company LP

    2.82%

  • Morgan Stanley - Brokerage Accounts

    2.47%

  • Baillie Gifford & Co Limited.

    2.29%

Company Information

at illumina, our goal is to apply innovative technologies and revolutionary assays to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago. these studies will help make the realization of personalized medicine possible. with such rapid advances in technology taking place, it is mission critical to have solutions that are not only innovative, but flexible, scalable, and complete with industry-leading support and service. as a global company that places high value on collaborative interactions, rapid delivery of solutions, and prioritizing the needs of its customers, we strive to meet this challenge. illumina’s innovative, array-based solutions for dna, rna, and protein analysis serve as tools for disease research, drug development, and the development of molecular tests in the clinic.

Organization
Illumina Inc.
Employees
10590
CEO
Mr. Jacob Thaysen Ph.D.
Industry
Health Technology

FAQs